See more : Thai Union Group Public Company Limited (TUFUF) Income Statement Analysis – Financial Results
Complete financial analysis of Charles River Laboratories International, Inc. (CRL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Charles River Laboratories International, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Aritzia Inc. (ATZ.TO) Income Statement Analysis – Financial Results
- Avalara, Inc. (AVLR) Income Statement Analysis – Financial Results
- Ten Ren Tea Co., Ltd. (1233.TW) Income Statement Analysis – Financial Results
- NextEra Energy, Inc. Series N J (NEE-PN) Income Statement Analysis – Financial Results
- RAIZNEXT Corporation (6379.T) Income Statement Analysis – Financial Results
Charles River Laboratories International, Inc. (CRL)
About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.13B | 3.98B | 3.54B | 2.92B | 2.62B | 2.27B | 1.86B | 1.68B | 1.36B | 1.30B | 1.17B | 1.13B | 1.14B | 1.13B | 1.20B | 1.34B | 1.23B | 1.06B | 1.12B | 766.92M | 613.72M | 554.63M | 465.63M | 306.59M | 219.28M | 193.30M |
| Cost of Revenue | 2.63B | 2.51B | 2.21B | 1.85B | 1.66B | 1.43B | 1.16B | 1.03B | 832.21M | 825.00M | 770.63M | 737.45M | 740.41M | 748.66M | 773.18M | 832.78M | 752.44M | 651.78M | 693.49M | 468.35M | 380.06M | 345.65M | 298.38M | 171.45M | 120.91M | 122.55M |
| Gross Profit | 1.50B | 1.46B | 1.33B | 1.07B | 958.31M | 840.07M | 702.31M | 646.67M | 531.09M | 472.66M | 394.90M | 392.08M | 402.24M | 384.76M | 429.37M | 510.71M | 478.19M | 406.61M | 428.74M | 298.57M | 233.67M | 208.98M | 167.25M | 135.14M | 98.37M | 70.75M |
| Gross Profit Ratio | 36.39% | 36.79% | 37.70% | 36.72% | 36.56% | 37.07% | 37.81% | 38.46% | 38.96% | 36.42% | 33.88% | 34.71% | 35.20% | 33.95% | 35.70% | 38.01% | 38.86% | 38.42% | 38.20% | 38.93% | 38.07% | 37.68% | 35.92% | 44.08% | 44.86% | 36.60% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 747.86M | 665.10M | 619.92M | 528.94M | 517.62M | 443.85M | 373.45M | 367.55M | 300.41M | 269.03M | 225.70M | 208.25M | 206.14M | 262.49M | 234.00M | 230.16M | 217.49M | 180.80M | 189.54M | 121.45M | 90.24M | 83.30M | 68.32M | 51.20M | 39.77M | 34.14M |
| Other Expenses | 0.00 | 146.58M | 124.86M | 111.88M | 89.54M | 13.26M | 38.54M | 11.90M | 3.01M | 10.72M | 7.17M | -3.27M | 21.80M | 24.41M | 28.45M | 30.31M | 33.51M | 37.64M | 58.17M | 16.80M | 4.88M | 3.41M | 8.65M | 18.87M | 15.64M | 1.29M |
| Operating Expenses | 885.30M | 811.68M | 744.78M | 640.81M | 607.16M | 508.68M | 414.82M | 409.25M | 324.64M | 294.99M | 243.50M | 226.32M | 227.94M | 286.89M | 262.44M | 260.47M | 251.00M | 218.43M | 247.72M | 138.24M | 95.11M | 86.72M | 76.97M | 70.07M | 55.41M | 35.43M |
| Cost & Expenses | 3.51B | 3.33B | 2.95B | 2.49B | 2.27B | 1.93B | 1.57B | 1.44B | 1.16B | 1.12B | 1.01B | 963.77M | 968.34M | 1.04B | 1.04B | 1.09B | 1.00B | 870.21M | 941.21M | 606.59M | 475.17M | 432.36M | 375.35M | 241.52M | 176.31M | 157.98M |
| Interest Income | 5.20M | 780.00K | 652.00K | 834.00K | 1.52M | 812.00K | 690.00K | 1.31M | 1.04M | 1.15M | 730.00K | 589.00K | 1.35M | 1.19M | 1.78M | 8.69M | 9.68M | 6.84M | 3.93M | 3.29M | 0.00 | 2.12M | 1.49M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 136.71M | 59.29M | 73.91M | 86.43M | 60.88M | 63.77M | 29.78M | 27.71M | 15.07M | 11.95M | 20.97M | 33.34M | 41.23M | 34.09M | 21.68M | 14.01M | 14.83M | 193.24M | 22.62M | 8.65M | 6.56M | 27.34M | 27.28M | 67.35M | 8.28M | 0.00 |
| Depreciation & Amortization | 314.12M | 303.87M | 265.54M | 234.92M | 198.10M | 161.78M | 131.16M | 126.66M | 24.23M | 25.96M | 17.81M | 18.07M | 21.80M | 24.41M | 28.45M | 30.31M | 88.92M | 85.13M | 104.64M | 48.18M | 31.12M | 25.73M | 28.58M | 18.87M | 15.64M | 10.90M |
| EBITDA | 1.03B | 1.04B | 854.29M | 759.15M | 581.73M | 507.23M | 457.89M | 377.29M | 305.38M | 285.99M | 255.54M | 244.36M | 260.48M | -205.15M | 263.20M | -355.82M | 321.81M | 273.30M | 274.81M | 210.64M | 138.55M | 147.99M | 90.28M | 83.93M | 58.61M | 46.22M |
| EBITDA Ratio | 24.99% | 24.80% | 23.17% | 26.28% | 21.48% | 18.11% | 19.82% | 17.39% | 16.92% | 15.69% | 14.52% | 16.28% | 17.16% | 10.79% | 16.07% | 73.43% | 25.80% | 25.73% | 25.47% | 27.09% | 27.52% | 26.46% | 25.42% | 27.02% | 25.82% | 23.94% |
| Operating Income | 617.26M | 650.98M | 589.86M | 432.73M | 351.15M | 331.38M | 287.50M | 237.42M | 206.45M | 177.67M | 151.40M | 165.77M | 174.31M | -298.51M | 166.93M | -449.76M | 227.19M | 188.17M | 181.02M | 160.32M | 138.55M | 122.27M | 90.28M | 65.06M | 42.96M | 35.33M |
| Operating Income Ratio | 14.95% | 16.37% | 16.66% | 14.80% | 13.40% | 14.62% | 15.48% | 14.12% | 15.14% | 13.69% | 12.99% | 14.68% | 15.25% | -26.34% | 13.88% | -33.48% | 18.46% | 17.78% | 16.13% | 20.90% | 22.58% | 22.04% | 19.39% | 21.22% | 19.59% | 18.27% |
| Total Other Income/Expenses | -35.98M | -27.99M | -109.15M | 14.39M | -47.07M | -49.70M | 8.67M | -14.50M | -11.02M | -75.00K | -13.07M | -36.02M | -41.64M | -35.57M | -17.82M | -10.14M | -9.77M | -11.61M | -17.13M | -9.86M | -5.92M | -37.75M | -27.78M | -39.35M | -10.28M | 507.00K |
| Income Before Tax | 581.28M | 622.99M | 480.71M | 447.11M | 304.08M | 281.68M | 296.96M | 222.92M | 195.43M | 177.60M | 138.33M | 129.75M | 132.66M | -334.08M | 149.11M | -461.01M | 217.42M | 176.56M | 160.41M | 152.53M | 132.63M | 114.40M | 69.48M | 25.71M | 32.69M | 35.83M |
| Income Before Tax Ratio | 14.08% | 15.67% | 13.58% | 15.29% | 11.60% | 12.43% | 15.99% | 13.26% | 14.33% | 13.69% | 11.87% | 11.49% | 11.61% | -29.48% | 12.40% | -34.31% | 17.67% | 16.68% | 14.29% | 19.89% | 21.61% | 20.63% | 14.92% | 8.39% | 14.91% | 18.54% |
| Income Tax Expense | 100.91M | 130.38M | 81.87M | 81.81M | 50.02M | 54.46M | 171.37M | 66.84M | 43.39M | 47.67M | 32.91M | 27.63M | 17.14M | 23.00K | 39.73M | 61.94M | 59.40M | 49.74M | 16.58M | 61.16M | 51.06M | 43.57M | 27.10M | 7.84M | 15.56M | 14.12M |
| Net Income | 474.62M | 486.23M | 390.98M | 364.30M | 252.02M | 226.37M | 123.36M | 154.77M | 149.31M | 126.70M | 102.83M | 97.30M | 109.57M | -336.67M | 114.44M | -521.84M | 154.41M | -55.78M | 142.00M | 89.79M | 80.15M | 50.13M | 35.41M | -11.22M | 17.12M | 23.38M |
| Net Income Ratio | 11.49% | 12.23% | 11.04% | 12.46% | 9.61% | 9.99% | 6.64% | 9.20% | 10.95% | 9.76% | 8.82% | 8.61% | 9.59% | -29.70% | 9.52% | -38.84% | 12.55% | -5.27% | 12.65% | 11.71% | 13.06% | 9.04% | 7.60% | -3.66% | 7.81% | 12.09% |
| EPS | 9.27 | 9.57 | 7.77 | 7.35 | 5.17 | 4.72 | 2.60 | 3.29 | 3.21 | 2.72 | 2.15 | 2.03 | 2.16 | -5.38 | 1.75 | -7.76 | 2.31 | -0.81 | 2.04 | 1.81 | 1.76 | 1.12 | 0.86 | -0.40 | 0.86 | 2.27 |
| EPS Diluted | 9.22 | 9.48 | 7.60 | 7.20 | 5.07 | 4.62 | 2.54 | 3.23 | 3.13 | 2.66 | 2.12 | 2.01 | 2.14 | -5.38 | 1.74 | -7.76 | 2.25 | -0.80 | 1.96 | 1.67 | 1.64 | 1.06 | 0.80 | -0.35 | 0.86 | 2.27 |
| Weighted Avg Shares Out | 51.23M | 50.81M | 50.29M | 49.55M | 48.73M | 47.95M | 47.48M | 47.01M | 46.50M | 46.63M | 47.74M | 47.91M | 50.82M | 62.56M | 65.37M | 67.27M | 66.96M | 68.87M | 69.61M | 49.60M | 45.54M | 44.76M | 41.17M | 28.06M | 19.82M | 10.29M |
| Weighted Avg Shares Out (Dil) | 51.45M | 51.30M | 51.43M | 50.61M | 49.69M | 49.02M | 48.56M | 47.96M | 47.63M | 47.56M | 48.49M | 48.41M | 51.32M | 62.56M | 65.64M | 67.27M | 68.74M | 69.73M | 72.45M | 56.05M | 48.87M | 47.29M | 44.26M | 32.07M | 19.82M | 10.29M |
CRL Stock May Benefit From New Neuroscience Research Collaboration
Why Is Charles River (CRL) Down 5.3% Since Last Earnings Report?
CRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories' Directors and Officers for Breach of Fiduciary Duties
Charles River Laboratories: Changing Economics Reduces Compounding Ability (Rating Downgrade)
CHARLES RIVER ALERT: Bragar Eagel & Squire, P.C. is Investigating Charles River Laboratories International, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Why Charles River (CRL) International Revenue Trends Deserve Your Attention
Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)
Charles River (CRL) Q2 Earnings Beat Estimates, 2024 View Down
Charles River Laboratories International Inc (CRL) Q2 2024 Earnings Call Transcript
Charles River Labs Says It Expects Sales To Fall, Sending Its Stock Tumbling
Source: https://incomestatements.info
Category: Stock Reports